Literature DB >> 14640500

Epidemiologic and clinical characteristics of acute diarrhea with emphasis on Entamoeba histolytica infections in preschool children in an urban slum of Dhaka, Bangladesh.

Rashidul Haque1, Dinesh Mondal, Beth D Kirkpatrick, Selim Akther, Barry M Farr, R Bradley Sack, William A Petri.   

Abstract

The epidemiology, clinical features, nutritional status, and causative agents of diarrhea were studied in 289 Bangladeshi children (147 boys and 142 girls) 2-5 years old. The use of improved diagnostic tests for amebiasis enabled for the first time analysis of the contribution of Entamoeba histolytica to total diarrheal illness in this community setting. The average incidence rate of diarrhea was 1.8/child-year, and the average number of diarrheal days was 3.7 days/child-year over an average observation period of 2.8 years/child. Seventy-five percent of the diarrheal episodes were < or = 2 days in duration. Persistent diarrhea was relatively uncommon (0.2% of the children) and chronic diarrhea was observed in only one episode. Compared with malnourished and/or stunted children, better-nourished children experienced significantly fewer diarrheal episodes. The diarrheal incidence rate for children with blood group A was significantly less that that of the children with blood groups O and AB. The most frequent bacterial enteropathogens isolated from diarrheal stool specimens were enterotoxigenic Escherichia coli (9%) and Aeromonas species (9%), followed by Plesimonas shigelloides (4%) and Shigella flexneri (3.8%). Rotavirus was the most common viral agent isolated from diarrheal stool samples (5%). Giardia lamblia, Cryptosporidium parvum, and E. histolytica were identified in 11%, 8.4%, and 8%, respectively, of the diarrheal stool specimens. Dysentery was observed in 7.7% of all diarrheal episodes. The most common pathogens isolated from dysenteric stool were S. flexneri (11.6%), Aeromonas sp. (10%), E. histolytica (8.7%), Campylobacter jejunii (5.8%), P. shigelloides (4.3%), and A. caviae (4.3%). The overall incidence rate of E. histolytica-associated diarrhea was 0.08/child-year. Visible blood and hemoccult test-detected blood loss was found in 7% and 25%, respectively, of cases of E. histolytica-associated diarrhea. Children who had recovered from a diarrheal episode with E. histolytica, but not E. dispar, had half the chance of developing subsequent E. histolytica-associated diarrhea, consistent with the development of species-specific acquired immunity. In conclusion, the use of modern diagnostic tests demonstrated that E. histolytica contributed to overall morbidity from diarrheal illness. Understanding the etiology, frequency, and consequences of acute diarrhea in children from a developing country should aid in the design of interventions to improve child health.

Entities:  

Mesh:

Year:  2003        PMID: 14640500

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  63 in total

1.  Etiology of acute diarrhea in adults in southwestern Nigeria.

Authors:  Amha Kebede; Anton M Polderman
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  A retromerlike complex is a novel Rab7 effector that is involved in the transport of the virulence factor cysteine protease in the enteric protozoan parasite Entamoeba histolytica.

Authors:  Kumiko Nakada-Tsukui; Yumiko Saito-Nakano; Vahab Ali; Tomoyoshi Nozaki
Journal:  Mol Biol Cell       Date:  2005-08-24       Impact factor: 4.138

3.  Evaluation of Entamoeba histolytica antigen and antibody point-of-care tests for the rapid diagnosis of amebiasis.

Authors:  Megan Leo; Rashidul Haque; Mamun Kabir; Shantanu Roy; Rita Marie Lahlou; Dinesh Mondal; Egbert Tannich; William A Petri
Journal:  J Clin Microbiol       Date:  2006-10-11       Impact factor: 5.948

4.  CD4+ and CD8+ T cell- and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine.

Authors:  Xiaoti Guo; Lisa Barroso; David M Lyerly; William A Petri; Eric R Houpt
Journal:  Vaccine       Date:  2010-11-21       Impact factor: 3.641

5.  Comparison of clinical and laboratory characteristics of intestinal amebiasis with shigellosis among patients visiting a large urban diarrheal disease hospital in Bangladesh.

Authors:  Sumon Kumar Das; Mohammod Jobayer Chisti; Mohammad Abdul Malek; Mohammed Abdus Salam; Tahmeed Ahmed; Abu Syed Golam Faruque; Dinesh Mondal
Journal:  Am J Trop Med Hyg       Date:  2013-06-17       Impact factor: 2.345

Review 6.  Enteric infections, diarrhea, and their impact on function and development.

Authors:  William A Petri; Mark Miller; Henry J Binder; Myron M Levine; Rebecca Dillingham; Richard L Guerrant
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

7.  Chlorination of Household Drinking Water Among Cholera Patients' Households to Prevent Transmission of Toxigenic Vibrio cholerae in Dhaka, Bangladesh: CHoBI7 Trial.

Authors:  Mahamud-Ur Rashid; Christine Marie George; Shirajum Monira; Toslim Mahmud; Zillur Rahman; Munshi Mustafiz; K M Saif-Ur-Rahman; Tahmina Parvin; Sazzadul Islam Bhuyian; Fatema Zohura; Farzana Begum; Shwapon Kumar Biswas; Shamima Akhter; Xiaotong Zhang; David Sack; R Bradley Sack; Munirul Alam
Journal:  Am J Trop Med Hyg       Date:  2016-10-03       Impact factor: 2.345

8.  Analysis of the Bacterial Diversity in Liver Abscess: Differences Between Pyogenic and Amebic Abscesses.

Authors:  Miriam E Reyna-Fabián; Valeria Zermeño; Cecilia Ximénez; Janin Flores; Miguel F Romero; Daniel Diaz; Jesús Argueta; Patricia Moran; Alicia Valadez; René Cerritos
Journal:  Am J Trop Med Hyg       Date:  2015-11-16       Impact factor: 2.345

9.  Human intestinal parasites.

Authors:  Rashidul Haque
Journal:  J Health Popul Nutr       Date:  2007-12       Impact factor: 2.000

10.  A simulation model for diarrhoea and other common recurrent infections: a tool for exploring epidemiological methods.

Authors:  W-P Schmidt; B Genser; Z Chalabi
Journal:  Epidemiol Infect       Date:  2008-10-08       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.